Treatments and Outcomes in Oligometastatic Soft Tissue Soft Sarcoma - A Single Centre Retrospective Analysis.

Autor:	Walls GM; Royal Marsden NHS Foundation Trust, London, U.K.; wallsgerard@gmail.com.; Patrick G Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, U.K., Zaidi SH; Royal Marsden NHS Foundation Trust, London, U.K.; Institute for Cancer Research, London, U.K., Fotiadis N; Royal Marsden NHS Foundation Trust, London, U.K., Jordan S; Royal Marsden NHS Foundation Trust, London, U.K.; Royal Brompton & Harefield Trust, London, U.K., Maruzzo M; Royal Marsden NHS Foundation Trust, London, U.K.; Veneto Institute of Oncology IOV-IRCCS, Padua, Italy., Hamid I; Royal Marsden NHS Foundation Trust, London, U.K., Al-Muderis O; Royal Marsden NHS Foundation Trust, London, U.K., Khabra K; Royal Marsden NHS Foundation Trust, London, U.K., Benson C; Royal Marsden NHS Foundation Trust, London, U.K.; Institute for Cancer Research, London, U.K., Jones RL; Royal Marsden NHS Foundation Trust, London, U.K.; Institute for Cancer Research, London, U.K., Judson IR; Institute for Cancer Research, London, U.K., Miah AB; Royal Marsden NHS Foundation Trust, London, U.K.; Institute for Cancer Research, London, U.K.
Jazyk:	angličtina
Zdroj:	Anticancer research [Anticancer Res] 2021 Oct; Vol. 41 (10), pp. 5089-5096.
DOI:	10.21873/anticanres.15325
Abstrakt:	Background/aim: Distinguishing true oligometastatic disease from early polymetastatic disease is vital in patients with soft tissue sarcoma as contemporary treatment strategies differ significantly. Clinical factors such as tumour biology, organ involved, number of lesions, and patient fitness influence clinical decisions. Patients and Methods: A retrospective search of a prospective database identified patients with new distant relapse, treated between 2009 and 2012. Results: A total of 223 patients were included, and oligometastases were diagnosed in 81 (36%) patients, which were pulmonary in just over half of cases. These were treated with local therapy in 66 of 89 cases, and 7 patients received subsequent treatment for additional oligometastases. Metastasectomy was the most common treatment modality. A total of 16/66 patients (24%) underwent active surveillance for >6 months prior to local therapy. Conclusion: Patients with oligometastatic disease can experience durable disease control with timely multimodality treatment approaches for evolving metastatic disease, where disease biology allows. (Copyright © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu